

## CLAIMS

1. A kit comprising a Fab, wherein the Fab comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:2, wherein the kit is for use in the treatment of a TSLP-related condition, wherein the TSLP-related condition is sepsis, septic shock, rheumatoid arthritis, asthma-COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
2. A kit comprising a Fab, wherein the Fab comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2, wherein the kit is for use in the treatment of a TSLP-related condition, wherein the TSLP-related condition is sepsis, septic shock, rheumatoid arthritis, asthma-COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
3. A kit comprising a Fab, wherein the Fab comprises a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:2, wherein the kit is for use in the treatment of a TSLP-related condition, wherein the TSLP-related condition is sepsis, septic shock, rheumatoid arthritis, asthma-COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
4. The kit according to any of claims 1 to 3, wherein the Fab is an IgG1 Fab.
5. The kit according to any preceding claim, wherein the Fab shows less than 10% monomer loss following incubation at 45°C in 1 X PBS for 2 weeks, wherein monomer is determined by HP-SEC.
6. A kit according to any preceding claim, wherein the Fab is provided in the form of a pharmaceutical composition.
7. A vector comprising a nucleic acid, wherein the nucleic acid encodes a Fab, wherein the Fab comprises a heavy chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:2.

8. A host cell comprising the vector of claim 7 or a nucleic acid, wherein the nucleic acid encodes a Fab, wherein the Fab comprises a heavy chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:2.
- 5 9. A method of producing a Fab comprising culturing the host cell of claim 8, expressing the Fab and purifying the Fab.
10. A Fab obtainable from the method of claim 9.
11. A Fab comprising a heavy chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:2 for use in the treatment of sepsis, septic shock, rheumatoid arthritis, COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
- 10 12. Use of a Fab comprising, having, or consisting of a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:2 in the manufacture of a medicament for the treatment of sepsis, septic shock, rheumatoid arthritis, COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis, wherein a therapeutically effective amount of the Fab is to be administered to a subject in need thereof.
- 15 20 13. Use of a Fab comprising a heavy chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain comprising, having, or consisting of the amino acid sequence set forth in SEQ ID NO:2 in the manufacture of a medicament for the treatment of sepsis, septic shock, rheumatoid arthritis, COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
- 25 14. The Fab for use according to claim 11, or the use according to claim 12 or 13, wherein the Fab is an IgG1 Fab.
15. Use of the kit according to any of claims 1 to 6 in the manufacture of a medicament for treating sepsis, septic shock, rheumatoid arthritis, COPD overlap syndrome (ACOS), chronic bronchitis, emphysema, chronic rhinosinusitis with or without nasal polyps, vasculitis, GvHD, uveitis, chronic idiopathic urticaria, sinusitis or pancreatitis.
- 30